$Cryoport (CYRX.US)$ VGXI Selects Cryoport for Biostorage, Bioservices and Supply Chain Solutions to Advance Next-Generation Therapies Cryoport, Inc. (NASDAQ: CYRX) and VGXI, Inc. have announced a strategic partnership to support biopharmaceutical companies in developing cell and gene therapies and mRNA-based treatments. The collaboration will commence in October 2024, with Cryoport Systems providing biostorage and bioservices from its Houston, Texas facility for plasmid DNA products manufact...
Despite Cryoport's superior revenue outlook, its P/S ratio is not reflecting this positive outlook, suggesting that the market may be pricing in some risks. If the analysts' forecasts are accurate, the stock could be undervalued at its current price.
Insider selling at Cryoport, Inc. over the past year, especially in recent months, may worry shareholders. However, significant insider ownership indicates alignment with other shareholders. The absence of insider buying in the last three months is noteworthy.
Cryoport's debt levels appear manageable, given healthy cash reserves and short-term assets. However, meeting future obligations will hinge on its profitability, an area where the company's performance has faltered. Cryoport saw modest revenue growth and a cash outflow last year.
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Cryoport Stock Forum
VGXI Selects Cryoport for Biostorage, Bioservices and Supply Chain Solutions to Advance Next-Generation Therapies
Cryoport, Inc. (NASDAQ: CYRX) and VGXI, Inc. have announced a strategic partnership to support biopharmaceutical companies in developing cell and gene therapies and mRNA-based treatments. The collaboration will commence in October 2024, with Cryoport Systems providing biostorage and bioservices from its Houston, Texas facility for plasmid DNA products manufact...
No comment yet